Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study.

ABSTRACT:

Aim

To assess the efficacy of pegaptanib as maintenance therapy in neovascular age-related macular degeneration (NV-AMD) patients after induction therapy.

Methods

A phase IV, prospective, open-label, uncontrolled exploratory study including subjects with subfoveal NV-AMD who had had one to three induction treatments 30-120 days before entry and showed investigator-determined clinical/anatomical NV-AMD improvement. Lesions in the study eye were: any subtype, 12 or fewer disc areas; postinduction centre point thickness (CPT) 275 μm or less or thinning of 100 μm or more (optical coherence tomography); visual acuity (VA) 20/20-20/400. Intravitreal pegaptanib 0.3 mg was administered as maintenance every 6 weeks for 48 weeks with follow-up to week 54. Booster treatment additional

SUBMITTER: Friberg TR 

PROVIDER: S-EPMC2991041 | biostudies-literature | 2010 Dec

REPOSITORIES: biostudies-literature